LATEST PRESS RELEASE
Amorfix announces strategic plan to centralize operations in South San Francisco and focus on neurodegenerative disease
January 12, 2015
Amorfix announces second quarter results for period ending September 30, 2014
November 12, 2014
Amorfix closes private placement and receives back rights for ALS antibody therapeutic development and commercialization
October 21, 2014
Amorfix appoints Dr. Elliot Goldstein and Mr. Warren Whitehead to Board of Directors
September 4, 2014
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.
Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.